NASDAQ: CARACARA THERAPEUTICS INC Stock
$8.37-0.57 (-6.38%)
Updated May 18, 2022
CARA Price
$8.37
Fair Value Price
$8.77
Market Cap
$448.56M
52 Week Low
$7.40
52 Week High
$18.93
P/E
-4.68x
P/B
2.2x
P/S
25.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.88M
Earnings
-$92.89M
Gross Margin
92%
Operating Margin
-358.88%
Profit Margin
-358.9%
Debt to Equity
0.1
Operating Cash Flow
-$62M
Beta
1.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CARA Overview
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CARA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CARA ($8.37) is undervalued by 4.61% relative to our estimate of its Fair Value price of $8.77 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CARA ($8.37) is not significantly undervalued (4.61%) relative to our estimate of its Fair Value price of $8.77 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CARA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CARA due diligence checks available for Premium users.
CARA News
Valuation
CARA fair value
Fair Value of CARA stock based on Discounted Cash Flow (DCF)
Price
$8.37
Fair Value
$8.77
Undervalued by
4.61%
CARA ($8.37) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CARA ($8.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CARA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CARA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.68x
Industry
-2.74x
Market
21.6x
CARA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.2x
Industry
4x
CARA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CARA's financial health
Profit margin
Revenue
$4.8M
Net Income
-$27.7M
Profit Margin
-579.3%
CARA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CARA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$223.9M
Liabilities
$19.8M
Debt to equity
0.1
CARA's short-term assets ($151.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CARA's short-term assets ($151.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CARA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CARA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.5M
Investing
$33.4M
Financing
$3.0k
CARA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CARA vs Biotech Stocks
CARA THERAPEUTICS Stock FAQ
©2022 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.